Prospects for combined use of oncolytic viruses and CAR T-cells

Prospects for combined use of oncolytic viruses and CAR T-cells

Abstract With the approval of talimogene laherparepvec (T-VEC) for inoperable locally advanced or metastatic malignant melanoma in the USA and Europe, oncolytic virotherapy is now emerging as a viable therapeutic option for cancer patients. In parallel, following the favourable results of several cl...

Full description

Bibliographic Details
Main Authors: Adam Ajina, John Maher
Format: Article
Language:English
Published: BMJ Publishing Group 2017-11-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Oncolytic virus
Chimeric antigen receptor
CAR T-cell
Adoptive cell transfer
Combination strategies
Synergism
Online Access:http://link.springer.com/article/10.1186/s40425-017-0294-6

Internet

http://link.springer.com/article/10.1186/s40425-017-0294-6

Similar Items